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Objective: We examined whether anxiety has incremental
value to depressive symptoms in predicting health status in
patients undergoing percutaneous coronary intervention (PCI)
treated in the drug-eluting stent era. Methods: A series of
consecutive patients (n=692) undergoing PCI as part of the
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology
Hospital registry completed the Hospital Anxiety and Depression
Scale at 6 months and the Short-Form Health Survey (SF-36) at 6
and 12 months post-PCI. Results: Of 692 patients, 471 (68.1%)
had no symptoms of anxiety nor depression, 62 (9.0%) had
anxiety only, 59 (8.5%) had depressive symptoms only, and 100
(14.5%) had co-occurring symptoms. There was an overall
significant improvement in health status between 6 and 12 months
post-PCI (Pb.001); the interaction effect for time by psycholog-0022-3999/06/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jpsychores.2006.06.009
4 Corresponding author. CoRPS, Department of Medical Psychology,
Room P503a, Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE
Tilburg, The Netherlands. Tel.: +31 13 466 2503; fax: +31 13 466 2370.
E-mail address: s.s.pedersen@uvt.nl (S.S. Pedersen).ical symptoms was also significant (P=.003). Generally, patients
with co-occurring symptoms reported significantly poorer health
status compared with the other three groups (Ps b.001). Patients
with co-occurring symptomatology were also at greater risk of
impaired health status on six of the eight subdomains of the SF-36
compared with the other three symptom groups, adjusting for
baseline characteristics and health status at 6 months. Conclusion:
Patients with co-occurring symptoms of anxiety and depression
reported poorer health status compared with anxious or depressed-
only patients and no-symptom patients, showing that anxiety has
incremental value to depressive symptoms in identifying PCI
patients at risk for impaired health status treated in the drug-
eluting stent era.
D 2006 Elsevier Inc. All rights reserved.Keywords: Anxiety; Depressive symptoms; Drug-eluting stents; Health status; Percutaneous coronary interventionIntroduction
The impact of depression on health outcomes has been
examined extensively in patients with cardiovascular dis-
ease, with depression being associated with increased
mortality [1,2], impaired health status [3], and declines in
health status [4]. Hence, not surprisingly, depression is the
first psychosocial factor to gain risk factor status on par withtraditional biomedical factors [5]. By contrast, there has been
less interest in anxiety, and available evidence on the impact
of anxiety on mortality is conflicting [6 –11]. Although
anxiety has been shown to predict other health outcomes,
such as health status [7–10], little is known about the impact
of anxiety in combination with depression as a predictor of
impaired health status. Health status is gaining increasing
recognition as an important endpoint, and the study of health
status and its determinants was recently advocated as a
means by which to enhance patient-centred care and to
bridge the gap between research and clinical practice [12].
Evidence shows that anxiety and depression frequently
co-occur [13–17]. Not only does anxiety precede the onsetearch 61 (2006) 783–789
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has also been associated with greater severity of emotional
distress [15,16] and poor response to treatment [17] in
psychiatrically depressed patients. In contrast, the impact of
co-occurring anxiety and depression has received far less
attention in cardiac patients. Previous studies in these
patients have either examined the separate impact of anxiety
and depression [7–10] or the effect of a composite of
distress on health status [11].
Prior to the introduction of drug-eluting stents, restenosis
following percutaneous coronary intervention (PCI) has
been shown to have a negative impact on health status in
some [18,19] but not in all studies [20]. However, given that
the use of drug-eluting stents has led to a significant
reduction in the risk of restenosis and the need for
revascularisation [21–23], the health status of patients
treated with PCI may have generally improved, thereby
perhaps minimising the impact of psychological factors on
health status. To date, no study has examined the role of
anxiety and depression as predictors of health status in
patients treated with PCI in the drug-eluting stent era.
The purpose of the current study was to examine whether
anxiety provides added value to depressive symptoms in
predicting health status in PCI patients treated in the drug-
eluting stent era. We investigated whether patients with co-
occurring symptoms of anxiety and depression had more
impaired health status as compared to patients with no
symptoms or symptoms of anxiety or depression alone.Fig. 1. Overview of patient selection for the current study.Methods
Study design and participants
Unselected patients (n=875; 71% response rate) under-
going PCI as part of the Rapamycin-Eluting Stent Evaluated
at Rotterdam Cardiology Hospital (RESEARCH) registry
participated in the current study. Details of the RESEARCH
registry study design [24] and the psychological substudy
have been published elsewhere [25]. In brief, the registry
was designed to evaluate the efficacy of the sirolimus-
eluting stent. For this purpose, no patients were excluded
based on clinical or anatomical criteria in order to represent
patients seen in daily clinical practice. Later analyses have
shown that 68% of the RESEARCH patients would not
qualify for inclusion in clinical trials due to their more
complex medical profile [26].
Surviving patients at 6 and 12 months post-PCI were
asked to complete a set of psychological questionnaires.
Clinical variables were also obtained at 6 months. Assess-
ment at 6 months was chosen to ensure that patients were in
a stable medical condition. A similar approach has been
adopted in other studies [27–29]. Moreover, psychological
symptoms evaluated at the time of the PCI have been shown
to be a poor indicator of later psychological morbidity [30].
Only patients (n=692) who had a score on the Short-FormHealth Survey (SF-36) at both 6 and 12 months post-PCI
qualified for inclusion (Fig. 1). Nonresponders on the SF-36
at 6 and 12 months were more likely to have had a previous
PCI compared with responders (32% vs. 23%; P=.03), but
no other differences were found between responders and
nonresponders on baseline characteristics.
The local medical ethics committee approved the study
protocol, and the study was conducted in accordance with
the Helsinki Declaration. Every patient provided written
informed consent.Materials
Demographic and clinical variables
Demographic variables included sex and age. Clinical
variables were prospectively collected at the time of the
index procedure and included prior myocardial infarction
(MI), prior PCI, prior coronary artery bypass graft (CABG)
surgery, sirolimus-eluting stent or bare metal stent implan-
tation, multivessel disease, hypertension, dyslipidemia,
diabetes mellitus, renal impairment, smoking status, and
cardiac medication [aspirin, beta-blockers, calcium antago-
nists, nitrates, angiotensin-converting enzyme (ACE) inhib-
itors, and statins].
Anxiety and depressive symptoms
Anxiety and depressive symptoms were assessed with
the 14-item Hospital Anxiety and Depression Scale (HADS)
[31]. Seven items contribute to each of the two subscales
and are answered on a 4-point Likert scale from 0 to 3 (score
range, 0–21). A cutoff score z8 for both subscales may be
used to quantify patients with likely anxiety and depressive
Table 1














Females 25 34 27 42 .005




39 55 34 46 .05
Prior cardiac
historyb
52 50 63 48 .33
Recent cardiac
eventc
5 8 14 7 .08
Multivessel
disease
51 45 56 55 .56
Hypertensiond 36 44 29 48 .04
Dyslipidemiae 80 79 83 79 .93
Diabetes mellitusd 12 15 17 20 .13
Renal impairmentf 31 31 34 36 .76
Current smokingg 29 48 24 41 .001
Medication
Aspirin 97 95 93 95 .39
Beta-blockers 98 98 98 97 .89
Calcium
antagonists
47 44 54 49 .67
Nitrates 8 18 7 14 .02
ACE inhibitors 26 15 25 29 .20
Statins 69 65 63 62 .46
a A post hoc Bonferroni correction was applied to all tests to adjust for
multiple comparisons, with Pb.003 (0.05/17) indicating statistical signifi-
cance.
b MI, CABG, or PCI prior to the index PCI.
c MI, CABG, or PCI between 6 and 12 months post-PCI.
d Present if being treated for the condition.
e Total cholesterol levels N240 mg/dl or on lipid-lowering medication.
f Indicated by creatinine clearance b61 ml/min.
g Based on self-report.
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between sensitivity and specificity [32]. The HADS is a
valid and reliable instrument [32] and has been shown to
predict mortality in patients referred for exercise testing
[33]. The HADS was administered 6 months post-PCI.
Health status
Health status was assessed with the generic SF-36 that
comprises eight health status subdomains, i.e., Role
Physical Functioning, Role Emotional Functioning, Phys-
ical Functioning, Mental Health, Vitality, Social Function-
ing, Bodily Pain, and General Health [34]. Scale scores are
obtained by summing the items together within a domain,
dividing this outcome by the range of scores and then
transforming the raw scores to a scale from 0 to 100. A
higher score on the SF-36 subdomains represents better
functioning, with a high score on the Bodily Pain scale
indicating freedom from pain. The scale has good reliability,
with Cronbach’s alpha ranging from .65 to .96 for all
subscales [35]. The SF-36 was administered 6 and
12 months following PCI.
Statistical analyses
Prior to statistical analyses, four psychological symptom
groups were created on the basis of anxiety and depressive
symptoms at 6 months, using a standardized cutoff z8 to
indicate likely symptomatology [32]: (1) no symptoms, (2)
anxiety, (3) depressive symptoms, and (4) co-occurring
symptoms. The chi-square test (Fisher’s exact test when
appropriate) was used to compare the four psychological
symptom groups on baseline characteristics. A post hoc
Bonferroni correction was applied to all tests to adjust for
multiple comparisons with Pb.003 (0.05/17) indicating
statistical significance. Analysis of variance (ANOVA) for
repeated measures was used to assess the impact of the four
psychological symptom groups on health status over time,
using the SF-36 subscales as continuous scores. A post hoc
Bonferroni correction was also used for this analysis to
determine statistical significance between the four psycho-
logical symptom groups. Multivariable logistic regression
analyses were performed to investigate the impact of
psychological symptoms on health status, using the no-
symptom group as reference group. Prior to these analyses,
the subdomains of the SF-36 were dichotomised, with the
lowest tertile indicating impaired health status. Others have
also advocated dichotomisation of health status measures in
order to enhance clinical interpretability [36]. In the
multivariable analyses, we adjusted for sex, age z60 years,
sirolimus-eluting or bare metal stent implantation, prior
cardiac history, recent cardiac event (MI, PCI, and CABG
occurring between 6 and 12 months post-PCI), multivessel
disease, hypertension, dyslipidemia, diabetes, renal impair-
ment, smoking, and health status at 6 months. All tests were
two tailed. Odds ratios (ORs) with 95% confidence intervals(CIs) are reported. All statistical analyses were performed
using SPSS 12.0.1 for Windows.Results
Patient characteristics stratified by psychological symptoms
Baseline characteristics stratified by the four psycholog-
ical symptom groups are presented in Table 1. Of 692
patients, 471 (68.1%) had no symptoms of anxiety or
depression, 62 (9.0%) had anxiety only, 59 (8.5%) had
depressive symptoms only, and 100 (14.5%) had co-
occurring symptoms. Patients with depressive symptoms
were generally older (age z60 years) than the other three
symptom groups, whereas patients with anxiety were more
likely to smoke. No other statistically significant differences
were found between the four groups on demographic and
clinical risk factors and cardiac medication based on a
S.S. Pedersen et al. / Journal of Psychosomatic Research 61 (2006) 783–789786significance level of Pb.003 that was applied to adjust for
multiple comparisons.
Health status at 6 and 12 months
There was a main effect for time, with ANOVA for
repeated measures revealing a significant improvement in
health status between 6 and 12 months post-PCI
[F(1,688)=24.910; Pb.001]. The interaction effect for
time by psychological symptoms was also significant
[F(3,688)=4.671; P=.003]. This indicates that improve-
ment in health status varied according to psychological
symptom group, with the depressive symptomatology
group and the co-occurring anxiety and depression group
generally improving more than the no-symptomatology
and anxious group (Fig. 2). Of note, the four symptom
groups differed markedly on the health status subdomainsFig. 2. Health status at 6 and 12 months stratified by psychological symptoms at 6
indicates better health status, with a high score on bodily pain representing absenof the SF-36 [F(3,688)=159.018; Pb.001], with all post
hoc comparisons being significant (Pb.001) except for the
comparison between groups with anxiety vs. depressive
symptoms only (P=.27) (Fig. 2). For all subdomains of
the SF-36, patients who suffered from co-occurring
symptoms of anxiety and depression reported significantly
lower health status compared with the other three groups.
Similarly, patients with depressive symptoms only reported
lower health status compared with patients with anxiety
(except for vitality and bodily pain). The no-symptom
group reported the best health status of all groups. This
pattern was consistent both at 6 and 12 months. Patients
with co-occurring symptoms scored 50 or lower on all
eight health status subdomains of the SF-36 at 6 months
and on five of the eight subdomains at 12 months, bearing
in mind that the possible score range for the subdomains
is 0–100.months. ANOVA for repeated measures (univariable analysis); a high score
ce of pain.
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status at 12 months
In multivariable logistic regression analyses, patients who
had co-occurring symptoms of anxiety and depression were
at increased risk of experiencing impaired health status
compared with patients with no symptoms, adjusting for
demographic and clinical factors and health status at
6 months (Table 2). For six of the eight subdomains of the
SF-36, the risk to patients with co-occurring symptoms was
larger than that to patients with depressive symptoms alone
(Table 2). The largest differences in risk between patients
with co-occurring symptoms and patients with depressed
symptomatology were found on Role Physical Functioning
(OR 4.06 vs. OR 2.13), Role Emotional Functioning (OR
4.87 vs. OR 2.70), and Vitality (OR 8.33 vs. OR 5.79). This
indicates that anxiety has incremental value to depressive
symptoms when wanting to identify patients with impaired
health status. Other independent predictors of impaired
health status were female sex, age z60 years, sirolimus-
eluting stent implantation, prior cardiac history, recent
cardiac event, renal impairment, multivessel disease, and
health status at 6 months, depending on the health status
subdomain in question (results not shown).Table 2
Independent predictive value of psychological symptoms on health status at
12 monthsa
Health status
subdomain Psychological symptomsb OR [95% CI] P
Role Physical
Functioning
Anxiety 1.92 [1.04–3.57] .04
Depressive symptoms 2.13 [1.14–3.97] .02
Co-occurring symptoms 4.06 [2.35–7.02] b.001
Role Emotional
Functioning
Anxiety 2.38 [1.20–4.72] .01
Depressive symptoms 2.70 [1.40–5.19] .003
Co-occurring symptoms 4.87 [2.74–8.65] b.001
Physical
Functioning
Anxiety 1.63 [0.77–3.48] .20
Depressive symptoms 1.95 [0.90–4.22] .09
Co-occurring symptoms 3.80 [1.92–7.53] b.001
Mental Health Anxiety 2.17 [1.14–4.14] .02
Depressive symptoms 3.94 [2.00–7.78] b.001
Co-occurring symptoms 3.63 [2.03–6.48] b.001
Vitality Anxiety 4.53 [2.34–8.77] b.001
Depressive symptoms 5.79 [3.01–11.15] b.001
Co-occurring symptoms 8.33 [4.32–16.06] b.001
Social
Functioning
Anxiety 3.52 [1.90–6.53] b.001
Depressive symptoms 6.49 [3.37–12.50] b.001
Co-occurring symptoms 6.09 [3.41–10.85] b.001
Bodily Pain Anxiety 2.49 [1.32–4.70] .005
Depressive symptoms 2.68 [1.42–5.05] .002
Co-occurring symptoms 3.42 [1.98–5.91] b.001
General Health Anxiety 3.12 [1.66–5.86] b.001
Depressive symptoms 1.71 [0.90–3.22] .10
Co-occurring symptoms 3.19 [1.87–5.47] b.001
a Multivariable analyses with adjustment for sex, age z60 years,
sirolimus-eluting or bare metal stent implantation, prior cardiac event,
recent cardiac event, multivessel disease, hypertension, dyslipidemia,
diabetes mellitus, renal impairment, current smoking, and health status at
6 months.
b Reference group had neither symptoms of anxiety nor depression.Discussion
To our knowledge, this is the first study to examine the
impact of co-occurring symptoms of anxiety and depression
on health status in patients undergoing PCI in general and in
the drug-eluting stent era in particular. We found that
patients with co-occurring symptoms reported a signifi-
cantly poorer health status on six of the eight subdomains of
the SF-36 compared with patients with depressed symptoms
only or no depression.
Previous studies have found depression and anxiety to
exert separate and independent detrimental effects on health
status [7–11]. In the current study, we found that patients
with co-occurring symptoms of anxiety and depression
reported significantly poorer health status compared with
patients with anxiety or depressed symptoms only or no
symptoms, adjusting for demographic and clinical factors
and health status at 6 months. These differences were not
only statistically significant but also clinically relevant with
patients with co-occurring symptoms scoring 50 or lower on
a scale from 0 to 100 on all eight health status subdomains
of the SF-36 at 6 months and on five of the eight
subdomains at 12 months. Although patients with depres-
sive symptomatology also were at increased risk of impaired
health status compared with the anxious and no-symptom
groups, their risk was lower on six of the eight subdomains
than that for patients with co-occurring symptoms. Co-
occurring symptoms of anxiety and depression have also
been associated with greater severity of emotional distress
[15,16] and poor response to treatment [17] in other patient
groups and in the general population [37]. Taken together,
these results show that anxiety enhances the detrimental
effect of depressive symptoms on health status.
Consistent with other studies, we found a general
improvement in health status between 6 and 12 months
post-PCI [10,38]. Although one previous study showed that
the deleterious effects of anxiety and depression on health
status remained stable over time [10], in the current study,
we found a significant interaction effect for time by
psychological symptoms, indicating that the symptom
groups had different rates of improvement. Although these
improvements were somewhat larger in the depressive
symptomatology and co-occurring symptom groups com-
pared with the anxious only and no-symptom groups,
neither of the former groups experienced clinically signifi-
cant improvements (N10 points) in health status. An
explanation for the improvements in the depressive and
co-occurring symptom groups relative to the other two
groups may be that their health status scores were relatively
low already at 6 months; in other words, in these two groups
there was still room for improvement over time, whereas the
anxious and no symptom groups at 6 months may already
have reached a plateau since they had higher scores.
The results of the current study have implications for
research and clinical practice. Anxiety and depression
should be studied in concert, as patients with co-occurring
S.S. Pedersen et al. / Journal of Psychosomatic Research 61 (2006) 783–789788symptoms report significantly poorer health status compared
with patients with anxiety or depressive symptoms alone.
Future studies are warranted that investigate whether
patients with co-occurring symptoms may also be at greater
risk of adverse prognosis.
This study has some limitations. Patients who died
between 0 and 6 months post-PCI did not have the
opportunity to complete the questionnaires, which may
have biased our results, as the sickest patients were
excluded. However, several have advocated that baseline
is not an optimal time point to assess psychological
symptoms and health status in PCI patients, as they are
not medically stable at this point in time [27–30]. Second,
the results may not be generalisable to the total sample due
to the relatively low response rate on questionnaires. Third,
we had no information on other psychiatric diagnoses, the
use of psychopharmaca, treatment by a psychiatrist, or
demographic variables (e.g., marital status) that may
potentially have had an influence on symptoms and health
status. Nevertheless, strengths of the study were the multiple
assessments of health status and that patients represented
those seen in daily clinical practice, as no exclusion criteria
were applied based on clinical presentation. Research
conducted in the breal worldQ has been advocated as a
means by which to bridge the gap between research and
clinical practice [4].
In conclusion, patients with co-occurring symptoms of
anxiety and depression reported poorer health status
compared with anxious or depressed-only or no-symptom
patients. More importantly, health professionals frequently
under-recognise the role of anxiety in depressed outpatients
[39] and in cardiac patients [40]. Symptoms of anxiety may
be persistent in cardiac patients, but only one out of three
anxious cardiac patients are asked about such symptoms
[40]. The present findings indicate that anxiety has
incremental value to depressive symptoms in predicting
impaired health status in PCI patients treated in the drug-
eluting stent era. As recommended in a recent paper
reporting on the high prevalence of psychiatric disorders
in patients with stable heart disease [13], it seems timely for
research and clinical practice to address this issue of co
morbidity and its potential consequences for health status
and prognosis.References
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